Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics ( (HRTX) ) has shared an announcement.
On August 8, 2025, Heron Therapeutics entered into a Cooperation Agreement with Rubric Capital Management, which involves changes to the company’s Board of Directors, including the appointment of a new director nominated by Rubric. Additionally, Heron Therapeutics has undertaken significant refinancing transactions, including amendments to its working capital facility and the issuance of convertible senior unsecured promissory notes, which closed on August 12, 2025. These strategic moves are expected to strengthen the company’s financial position and support its ongoing operations.
The most recent analyst rating on (HRTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics’ overall score is driven by financial instability and technical weakness, despite positive strategic initiatives and earnings call sentiment. The company’s high leverage and negative equity are significant risks, but recent strategic moves and revenue growth provide some optimism.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for patients suffering from cancer and pain management. The company is known for its innovative therapies and aims to enhance the lives of patients through its specialized products.
Average Trading Volume: 1,525,055
Technical Sentiment Signal: Strong Sell
Current Market Cap: $196.2M
For a thorough assessment of HRTX stock, go to TipRanks’ Stock Analysis page.